(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.16%.
Tempest Therapeutics's earnings in 2026 is -$26,262,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2026 to be -$19,605,426, with the lowest TPST earnings forecast at -$18,836,585, and the highest TPST earnings forecast at -$20,182,056. On average, 3 Wall Street analysts forecast TPST's earnings for 2027 to be -$17,703,407, with the lowest TPST earnings forecast at -$17,009,156, and the highest TPST earnings forecast at -$18,224,095.
In 2028, TPST is forecast to generate -$13,021,514 in earnings, with the lowest earnings forecast at -$12,510,866 and the highest earnings forecast at -$13,404,500.